Bioatla announces third quarter 2021 financial results and provides clinical and business update

San diego, nov. 15, 2021 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics, today announced financial results for the third quarter of 2021 and provided an update on its clinical progress and business. "bioatla continues to advance the progress of the potentially registration-enabling phase 2 clinical trials for our two lead cab product candidates as well as our other preclinical and pipeline programs.
BCAB Ratings Summary
BCAB Quant Ranking